Advanced glycation end products or AGEs are formed due to reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids present in the body. They play a vital role in pathogenesis of aging and several chronic diseases such as diabetes, cardiovascular disease, neurodegenerative diseases and kidney failure. AGE inhibitors have shown promise in preventing or slowing down the progression of such chronic conditions. The global Advanced Glycation End Products (AGEs) Market is estimated to be valued at US$ 3.2 billion in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and other age-related diseases is majorly augmenting growth of the advanced glycation end products market. There has been a significant rise in incidence of diabetes across the world in the past few decades. For instance, according to International Diabetes Federation’s Diabetes Atlas, approximately 463 million adults were living with diabetes in 2019 and this number is projected to rise to around 700 million by 2045. AGEs play a critical role in development and progression of diabetic complications. Their accumulation in tissues can lead to damage of various organs in diabetes patients. This is increasing demand for AGE inhibitors that can help manage diabetes and its associated comorbidities more effectively.
Segment Analysis
The global advanced glycation end products market is dominated by skin care products and supplements sub-segment. This is because skin aging is one of the visible effects of accumulation of AGEs in the body over time. Skin care products containing ingredients that inhibit the formation of AGEs or help reverse the existing ones are increasingly being used to reduce signs of aging such as wrinkles and pigmentation. Supplements containing antioxidants that block the formation of AGEs are also gaining prominence.
Key Takeaways
The global Advanced Glycation End Products market is expected to witness high growth over the forecast period.
Regional analysis: North America is currently the largest and dominating region in the global advanced glycation end products market. This is attributed to rising health consciousness, growing geriatric population, and strong presence of leading players in the region. The Asia Pacific region is expected to grow at the fastest pace during the forecast period due to rapidly aging population and growing disposable income in developing countries.
Key players: Key players operating in the advanced glycation end products market are Lonza Group AG, DSM, Evonik Industries AG, Medix Biochemica, Abcam PLC, Cell Biolabs, Inc., AMS Biotechnology (Europe) Limited, Sino Biological Inc, and BioVision Inc. Lonza Group AG is one of the leading players offering ingredients that inhibit AGE formation for food, beverage, supplement and skin care applications.
